28058593|t|Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review
28058593|a|Background Ceftaroline is a parentally administered cephalosporin that has an in vitro expanded spectrum of activity compared with other cephalosporins yet data is conflicting regarding its place in therapy. Aim of the Review To compare the efficacy and safety of ceftaroline against standard antibiotic regimens for community-acquired pneumonia (CAP) and complicated skin and skin structure infections (cSSSIs). Method The databases of MEDLINE, EBSCO, and Embase were searched up to June 2016. Manual review of references was completed and experts in the field were contacted for unpublished data. Randomized controlled trials of ceftaroline in CAP or cSSSI populations were included. Outcomes included clinical cure, mortality, adverse events, serious adverse events, and discontinuation due to adverse events. Meta-analysis was used to pool results for these outcomes. We performed subgroup analyses for gram positive infections in CAP and infections caused by methicillin-resistant Staphylococcus aureus in cSSSIs. Risk of bias was assessed for all studies. Results Six trials (three for each indication) were included, each of which had an unclear or high risk of bias in at least one domain. For CAP, ceftaroline was significantly more efficacious in achieving clinical cure than ceftriaxone [risk ratio (RR) 1.11, 95% confidence interval (CI) 1.04-1.19; I(2) = 47%]. For cSSSIs, there was no significant difference in clinical cure between ceftaroline and vancomycin plus aztreonam (RR 1.01, 95% CI 0.97-1.05; I(2) = 0%). No differences were found for overall mortality, serious adverse events, discontinuation due to adverse events, and overall adverse events. Conclusion Ceftaroline is a viable therapeutic alternative for patients with CAP and cSSSIs, yet identified risks of bias and poor external validity preclude it from being recommended as a first-line agent.
28058593	0	19	Ceftaroline fosamil	T109,T195	C2001525
28058593	24	52	community-acquired pneumonia	T047	C0694549
28058593	57	61	skin	T022	C1123023
28058593	66	91	skin structure infections	T046	C3714514
28058593	95	112	systematic review	T170	C1955832
28058593	124	135	Ceftaroline	T109,T195	C2001525
28058593	152	164	administered	T169	C1621583
28058593	165	178	cephalosporin	T109,T195	C3536856
28058593	191	199	in vitro	T080	C1533691
28058593	200	208	expanded	T082	C0205229
28058593	221	229	activity	T044	C1321418
28058593	230	238	compared	T052	C1707455
28058593	250	264	cephalosporins	T109,T195	C3536856
28058593	269	273	data	T078	C1511726
28058593	312	319	therapy	T061	C0087111
28058593	332	338	Review	T170	C1955832
28058593	342	349	compare	T052	C1707455
28058593	354	362	efficacy	T080	C1280519
28058593	367	373	safety	T068	C0036043
28058593	377	388	ceftaroline	T109,T195	C2001525
28058593	406	416	antibiotic	T195	C0003232
28058593	417	425	regimens	T061	C0040808
28058593	430	458	community-acquired pneumonia	T047	C0694549
28058593	460	463	CAP	T047	C0694549
28058593	469	515	complicated skin and skin structure infections	T046	C3714514
28058593	517	523	cSSSIs	T046	C3714514
28058593	537	546	databases	T170	C0242356
28058593	550	557	MEDLINE	T170	C0025141
28058593	559	564	EBSCO	T170	C0242356
28058593	570	576	Embase	T170	C0242356
28058593	608	649	Manual review of references was completed	T170	C3259354
28058593	654	661	experts	T097	C1522486
28058593	694	710	unpublished data	T170	C0887929
28058593	712	740	Randomized controlled trials	T062	C0206035
28058593	744	755	ceftaroline	T109,T195	C2001525
28058593	759	762	CAP	T047	C0694549
28058593	766	771	cSSSI	T046	C3714514
28058593	772	783	populations	T098	C1257890
28058593	799	807	Outcomes	T169	C1274040
28058593	817	830	clinical cure	T033	C3640840
28058593	832	841	mortality	T081	C0205848
28058593	843	857	adverse events	T046	C0877248
28058593	859	881	serious adverse events	T033	C1519255
28058593	887	902	discontinuation	T061	C4288399
28058593	910	924	adverse events	T046	C0877248
28058593	926	939	Meta-analysis	T170	C0282458
28058593	975	983	outcomes	T169	C1274040
28058593	998	1006	subgroup	T185	C1515021
28058593	1007	1015	analyses	T062	C0936012
28058593	1020	1044	gram positive infections	T047	C0085426
28058593	1048	1051	CAP	T047	C0694549
28058593	1056	1066	infections	T046	C3714514
28058593	1077	1120	methicillin-resistant Staphylococcus aureus	T007	C1265292
28058593	1124	1130	cSSSIs	T046	C3714514
28058593	1132	1136	Risk	T078	C0035647
28058593	1140	1144	bias	T078	C0242568
28058593	1166	1173	studies	T062	C2603343
28058593	1187	1193	trials	T062	C0681815
28058593	1274	1278	risk	T078	C0035647
28058593	1282	1286	bias	T078	C0242568
28058593	1315	1318	CAP	T047	C0694549
28058593	1320	1331	ceftaroline	T109,T195	C2001525
28058593	1355	1366	efficacious	T080	C1280519
28058593	1380	1393	clinical cure	T033	C3640840
28058593	1399	1410	ceftriaxone	T109,T195	C0007561
28058593	1412	1422	risk ratio	T081	C0242492
28058593	1424	1426	RR	T081	C0242492
28058593	1438	1457	confidence interval	T081	C0009667
28058593	1459	1461	CI	T081	C0009667
28058593	1491	1497	cSSSIs	T046	C3714514
28058593	1538	1551	clinical cure	T033	C3640840
28058593	1560	1571	ceftaroline	T109,T195	C2001525
28058593	1576	1586	vancomycin	T116,T195	C0042313
28058593	1592	1601	aztreonam	T109,T195	C0004521
28058593	1603	1605	RR	T081	C0242492
28058593	1616	1618	CI	T081	C0009667
28058593	1680	1689	mortality	T081	C0205848
28058593	1691	1713	serious adverse events	T033	C1519255
28058593	1715	1730	discontinuation	T061	C4288399
28058593	1738	1752	adverse events	T046	C0877248
28058593	1766	1780	adverse events	T046	C0877248
28058593	1793	1804	Ceftaroline	T109,T195	C2001525
28058593	1817	1840	therapeutic alternative	T061	C0949216
28058593	1845	1853	patients	T101	C0030705
28058593	1859	1862	CAP	T047	C0694549
28058593	1867	1873	cSSSIs	T046	C3714514
28058593	1890	1895	risks	T078	C0035647
28058593	1899	1903	bias	T078	C0242568
28058593	1908	1930	poor external validity	T033	C2924039
28058593	1971	1987	first-line agent	T195	C0003232